Isomerase Therapeutics announces closure of successful second round of seed investment

 November 30th, 2013--Cambridge

Isomerase Therapeutics Ltd. announces that it has closed a second round of seed investment. Isomerase is a drug discovery company based in Cambridge, UK which is developing second-generation biosynthetic engineering technologies and offers collaborations in this and related fields.
CEO of Isomerase Therapeutics, Dr Matt Gregory commented "We have had a very successful first few months of operation, and already have a number of exciting collaborations underway. This investment will enable us to continue to develop our next-generation synthetic biology tools which are fast and efficient to use and we are confident will continue the current revitalisation of natural products drug discovery."